List of Drugs in Development for Neurodegenerative Diseases

  title={List of Drugs in Development for Neurodegenerative Diseases},
  author={Myoung-Ok Kwon and Paul L. Herrling},
  journal={Neurodegenerative Diseases},
  pages={61 - 108}
Neurodegenerative diseases are an increasingly important issue in our society. There are, however, still many obstacles on the way to fi nding methods for cure. This table is intended to give an overview over neurodegenerative drugs that are currently in research and development in order to give the reader an idea about the complexity of drug discovery in this fi eld. This table is intended as a pointer to drugs and it is recommended to obtain additional information from the internet to check… 
Drugs and clinical trials in neurodegenerative diseases.
Until comprehensive knowledge on the pathologic processes underpinning neurodegenerative diseases is obtained, alternative study designs can be considered to identify disease modifiers and to reduce costs of clinical studies.
An update on pharmacological approaches to neurodegenerative diseases
In this review, the authors intend to survey new drugs in different clinical phases but not in the preclinical or discovery stages nor already in the market, with new molecules aimed at interrupting or at attenuating different pathogenic pathways of neurodegeneration and/or at ameliorating symptoms.
Non-cholinergic drug development for Alzheimer's disease
The provocative suggestion is offered that the biggest threat to identifying effective therapies may prove to be the implementation of enough treatment trials, and applying out-of-the-box prevention methodologies, rather than the discovery of promising candidates.
Prevention therapeutics of dementia
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease
Current pharmacotherapy for Alzheimer’s disease involves compounds that have been shown to improve cognition and global functions but have little impact on improving the eventual progression of the disease; however, there is evidence that other cholinesterases can play an important role in cholinergic function in the brain.
Current Medication Trends and Global Impact on Neurodegenerative Disorders
It was concluded that, the AYUSH medication system highly accepted for reliving the neuronal complications and managing all elevated parameters in patients suffering from neuronal disorders.
Immunomodulatory drug treatment in multiple sclerosis
  • R. Aharoni
  • Biology
    Expert review of neurotherapeutics
  • 2010
The potential of immunomodulatory treatments to counteract the inflammatory characteristics of MS and support neuroprotective processes is discussed.
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease
  • P. Jenner
  • Psychology, Biology
    Expert opinion on investigational drugs
  • 2005
Istradefylline is a novel adenosine A2A receptor antagonist currently in Phase III clinical trials for efficacy in patients with PD and results from Phase II clinical trials demonstrated that it provides a clinically meaningful reduction in ‘off’ time and an increased ‘on” time with non-troublesome dyskinesia in levodopa-treated patients with established motor complications.
Neuropeptides as possible targets in sleep disorders
The history of neuropeptide research is reviewed, followed by the sleep modulatory effects of various neuropepeptides, and general strategies for the pharmacological therapeutics targeting the peptidergic systems for sleep disorders are discussed.